Cytokinetics, Incorporated (CYTK) Financial Statements
Cytokinetics, Incorporated (CYTK) reported trailing twelve-month revenue of $67.7M (down 21.1% year on year) and net income of -$894.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$580.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CYTKCytokinetics, IncorporatedFollow CYTK — free
—
Price chart with a free account
- Market cap
- 8.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.01 | 0.03 | 0.05 | 0.03 | 0.11 | 0.01 | 0.03 | 0.03 | 0.06 | 0.07 | 0.09 | 0.01 | 0.02 | 0.09 | 0.07 | |
| Gross profit | 0.00 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Research & development | 0.04 | 0.04 | 0.05 | 0.04 | 0.05 | 0.06 | 0.09 | 0.09 | 0.09 | 0.10 | 0.16 | 0.24 | 0.33 | 0.34 | 0.42 | 0.40 | |
| Operating income | -0.05 | -0.04 | -0.03 | -0.01 | -0.04 | 0.02 | -0.11 | -0.09 | -0.10 | -0.09 | -0.19 | -0.32 | -0.50 | -0.54 | -0.61 | -0.71 | |
| Pre-tax income | -0.05 | -0.04 | -0.03 | -0.01 | -0.04 | 0.02 | -0.13 | -0.11 | -0.12 | -0.13 | -0.22 | -0.39 | -0.53 | -0.59 | -0.78 | -0.89 | |
| Income tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |
| Net income | -0.05 | -0.04 | -0.03 | -0.01 | -0.04 | 0.02 | -0.13 | -0.11 | -0.12 | -0.13 | -0.22 | -0.39 | -0.53 | -0.59 | -0.78 | -0.89 | |
| Diluted EPS ($) | -0.72 | -2.30 | -1.24 | -0.41 | -0.97 | 0.39 | -2.59 | -1.95 | -2.11 | -1.97 | -2.80 | -4.33 | -5.45 | -5.26 | -6.54 | -7.22 | |
| Diluted shares (bn) | 0.071 | — | — | 0.036 | 0.039 | 0.043 | 0.049 | — | — | 0.065 | 0.077 | 0.090 | 0.097 | 0.112 | 0.120 | — |
USD billions · SEC XBRL
Cytokinetics, Incorporated — questions
- What is Cytokinetics, Incorporated's revenue?
- $67.7M over the twelve months to 2026-06-30, down 21.1% year on year, from its 10-Q and 10-K filings.
- What is Cytokinetics, Incorporated's net income?
- -$894.0M over the twelve months to 2026-06-30.
- What is Cytokinetics, Incorporated's free cash flow?
- -$580.7M over the twelve months to 2026-06-30.
- What are Cytokinetics, Incorporated's diluted earnings per share?
- $-7.22 over the twelve months to 2026-06-30.
Every figure on this page comes from Cytokinetics, Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.